Last update 21 Nov 2024

Recombinant Polyvalent Norovirus Vaccine(Beijing Health Guard Biotechnology, Inc.)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

GastroenteritisNorovirus Infections

Inactive Indication-

Originator Organization

Beijing Health Guard Biotechnology, Inc.

Active Organization

Beijing Health Guard Biotechnology, Inc.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with Recombinant Polyvalent Norovirus Vaccine(Beijing Health Guard Biotechnology, Inc.)

100 Translational Medicine associated with Recombinant Polyvalent Norovirus Vaccine(Beijing Health Guard Biotechnology, Inc.)

100 Patents (Medical) associated with Recombinant Polyvalent Norovirus Vaccine(Beijing Health Guard Biotechnology, Inc.)

Literatures (Medical) associated with Recombinant Polyvalent Norovirus Vaccine(Beijing Health Guard Biotechnology, Inc.)

01 Nov 2018·Microbial PathogenesisQ3 · MEDICINE

Antigenic potential of a recombinant polyvalent DNA vaccine against pathogenic leptospiral infection

Q3 · MEDICINE

Article

Author: Nasiru Suleiman ; Abdul Rahim Mutalib ; Zunita Zakaria ; Bashiru Garba ; Siti Khairani Bejo ; Faruku Bande ; Abdul Rani Bahaman

Leptospirosis is a serious epidemic disease caused by pathogenic Leptospira species. The disease is endemic in most tropical and sub-tropical regions of the world. Currently, there is no effective polyvalent vaccine for prevention against most of the circulating serovars. Moreover, development of an efficient leptospiral vaccine capable of stimulating cross-protective immune responses against a wide range of serovars remains a daunting challenge. This, in part, is associated with the extensive diversity and variation of leptospiral serovars from region to region. In this study, a multi-epitope DNA vaccine encoding highly immunogenic epitopes from LipL32 and LipL41 was designed using in-silico approach. The DNA encoding antigenic epitopes was constructed from conserved pathogenic Leptospira genes (LipL32 and LipL41). Immunization of golden Syrian hamsters with the multi-epitope chimeric DNA vaccine resulted in the production of both agglutinating and neutralizing antibodies as evidence by MAT and in-vitro growth inhibition tests respectively. The antibodies produced reacted against eight different serovars and significantly reduced renal colonization following in vivo challenge. The vaccine was also able to significantly reduce renal colonization which is a very important factor responsible for persistence of leptospires among susceptible and reservoir animal hosts. In conclusion, the leptospiral multi-epitope chimeric DNA vaccine can serve as a potentially effective and safe vaccine against infection with different pathogenic leptospiral serovars.

01 Apr 2012·Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control

[Study on construction and immune protective effect of recombinant nucleic acid vaccine of Toxoplasma gondii].

Article

Author: Wei, Qing-Kuan

OBJECTIVETo construct the polyvalent recombinant nucleic acid vaccine of Toxoplasma gondii and measure its protective immune effect.METHODSThe gene of heat shock protein (HSP70) was amplified by PCR and inserted into the recombinant plasmid of pcDNA3-ROP2-p30 to construct recombinant polyvalent nucleic vaccine (pcDNA3-ROP2-p30-Hsp70). BALB/c mice were immunized with the constructed recombinant nucleic vaccine. CD4+ and CD8+ in the splenic lymphocytes and the lymphocytes in anticoagulant whole blood, the immune indices such as antibodies (IgG, IgM and IgA) and IFN-gamma, TNF, IL-2, IL-4, IL-12 in serum and splenic lymphocytes culture medium were detected, along with the challenge experiment. The protective immune responses that caused by the vaccine was measured by detecting the changes of immune indices of mice and the challenge experiment.RESULTS916 bp fragment of HSP70 gene was amplified by PCR. The recombinant polyvalent nucleic vaccine pcDNA3-ROP2-p30-HSP70 that included the whole open reading frame sequence of HSP gene was successfully constructed. The immunization results also showed this polyvalent nucleic vaccine could induce strong cellular and humoral responses by the detection of higher antibody titer in the experimental mice group, the increasing proliferation of CD4+ and CD8+ cells with significant deviations among the groups (F(CD4+) = 45.00, F(CD8+) = 15.01, all P < 0.01) and the apparent up-regulated levels of several cytokines IFN-gamma, IL-2 and IL-12 in serum and cultural supernatant of spleen cells, with more striking effect in serum. As a result of the challenge experiment, the immunized mice showed a longer survival time.CONCLUSIONThe recombinant nucleic acid vaccine pcDNA3-ROP2-p30-HSP70 possesses a strong immunogenicity and is able to induce an immune protection.

24 May 1999·Casopis lekaru ceskych

[Immunization in Lyme borreliosis--initial experience].

Article

Author: Bartůnĕk, P ; Mrázek, V

The ever increasing rate of new cases of Lyme disease, the tendency for chronicity in certain forms of the disease and especially the disputable effect of causal therapy resulted in strenuous efforts to develop an effective vaccine. The authors sum up recent experience with vaccination in the U.S.A. and Europe. Two studies in the U.S. during the years 1994 through 1997 included more than 20,000 probands. In one of the studies, coordinated by Steer (10,936 probands), during the first year twenty-two people of the vaccinated group contracted the disease compared to forty-three people of the non-vaccinated, i.e. placebo group. The vaccine efficacy was 49 percent. During the second year of the study, after the third dose of the vaccine, sixteen vaccinated people contracted the disease vs. sixty-six placebo probands. Vaccine efficacy was 76 percent. Its administration was accompanied by mild to moderate local or systemic reaction lasting up to three days. In the next study, coordinated by Sigal (10,305 probands) the vaccine efficacy was sixty-eight percent in the first year and ninety-two percent in the second, respectively. Both studies proved the vaccine to be safe and efficient in Lyme disease prevention. In comparison with these large long-term double-blind, placebo-controlled studies European research results presented to the medical community for the first time in 1998 in Vienna appear to be of lesser value. Recombinant polyvalent vaccine based on OspC lipoprotein isolated from Borrelia burgdorferi sensu lato was used but only eighty volunteers from Aland Islands participated in the study.

100 Deals associated with Recombinant Polyvalent Norovirus Vaccine(Beijing Health Guard Biotechnology, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroenteritis	Preclinical	CN	Beijing Health Guard Biotechnology, Inc.	12 Oct 2022
Norovirus Infections	Preclinical	CN	Beijing Health Guard Biotechnology, Inc.	12 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Recombinant Polyvalent Norovirus Vaccine(Beijing Health Guard Biotechnology, Inc.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation